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Venous access devices (VAD) are implanted routinely in younger patients 
with cancer in order to administer therapy. The use of these devices is 
assumed to deaease the anxiety of repeated venepuncture, and to improve 
safety and convenience of administration of all intravenous therapies 
needed to treat such patients. 
The aims of this dissertation were: 
(a) To review the records of all patients 21 years and younger with cancer 
who were treated at a single institution 
(b) To examine the complications that occurred due to the VAD. 
(e) To measure the quality of life of those patients at serial intervals and to 
determine the financial cost of the VAD. 
Materials and Methods 
There were 51 patients who had 54 VADs inserted. At each visit 18 patients 
completed a touch screen version of the EORTC QLQ-C30 questionaire 
and these results were compared for all visits. The results were divided into 
3 time intervals viz before the VAD insertion, at the time of insertion and 53 
days thereafter and after 54 days. 
Results 
The mean and median age of the 51 patients was 17 years and 37 were 
male. 21 Patients had sarcoma and 21 had a haematological malignancy. 
The complications encountered were 7 -port fradures", 2 sepsis, 1 each of 
erosion through skin, tilting of VAD, hemithorax and jugular vein thrombosis. 
Improvements of symptoms such as fatigue, nausea, appetite and insomnia 
occurred as time progressed. The functional sub-scales of cognitive, role 
and social deteriorated at the time of V AD placement. 
The cost of a VAD insertion was R9060 and to remove a VAD was R3700. 
The regular maintenance of a port cost R85.16 per flush. 
Conclusion 
The VAD is a safe, effective way to gain venous access in younger patients 
with cancer. The initial deterioration in quality of life scores at the time of 
placement of the VAD was replaced by a definite improvement to above 
baseline levels as time progressed. Fuf:t.I'e studies assessing the QOL in 
adolescents should use an adolescent directed questionaire. 
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1 (i) Orientation. background and motivation for the study: 
Over the past few decades with the advent of modern oncology, advances 
in treatment of patients, especially children less than 15 years of age, has 
been dramatic. This age group has been the main focus of treatment and 
research and this research has had a well organized strudure which has 
supported and aided in this success. Groups such as International Society 
of Paediatric Oncology (SlOP) have worked well in order to fully evaluate 
treatment regimes and study cancer and patient behaviour. 
The internationally accepted definition of childhood, which for the purposes 
of cancer registration is 0-14 years (Robison LL,1997). As an extension of 
this definition, in the SEER (Surveillance, Epidemiology and End Results) 
programme of the National Cancer InstiMe (NCI) in the United States (Ries 
LAG,1999), adolescence has been assigned to the 15-19 year age bracket. 
Adolescence has been defined in many ways, but it may be most effedively 
viewed as the time of transition between childhood and adulthood (Evans M, 
1996). The World Health Organization defines adolescents as individuals 
between 10 and 20 years of age. This definition allows for wide cultural 
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diversity. In our culture most 10 year olds will be seen as children. 
Adolescence can be seen as a continuum of development that 
encompasses patients from the age of 10 to 23 years, but which will be 
flexible at either end of his or her own needs and circumstances, and the 
developmental tasks required by the individual and by society. There are 
stages in this transition from childhood to adulthood and at the end of this 
time, adolescents are expected to emerge into adult life with a positive 
sense of self-worth, an established identity, a comfortable body image and 
the ability to form relationships with others of the same and opposite sex. A 
diagnosis of cancer at this aitical time is devastating and brings with it many 
difficulties for the patient including a dramatic effect on his quality of life. His 
family and friends as well as his health care professional will all encounter 
the difficulty along with the patient who has cancer diagnosed at this time. 
1 (ii) Incidence of Cancer in Adolescence 
Within the database of the SEER programme, the annual incidence rates of 
cancer in the adolescent is at a little more than 200 per million, which is 
higher than in a younger quintile (Kosary el, 1995). For the period 1973-
1995, the incidence rate in adolescents increased by 30% whilst the rate in 
childhood rose by 10%. This was mainly due to an increase in adolescents 
of malignant germ cell and lymphoid neoplasms (Table 1). 
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Annually about 1500 to 2000 patients in the UK are diagnosed with cancer 
between the ages of 15 and 25 years (Leonard R, 1995). In the USA the 
incidence of cancer in the age group 15-19 years is 20 new cases per 
100,000 per year. Incidence data from Canada and Australia are similar 
(Barr R, 1999 & Parkin OM, 1992). 
Cancer in adolescence: age specific incidence rates 
Table 1 
1975-1979 1980-1984 1985-1989 1990-1994 
Testicular germ cell tumors 
Non-Hodgkin's lymphoma 
Ovarian germ cell tumors 




22.1 26.7 24.9 28.4 
10.7 14.5 14.4 16.3 
7.9 8.3 11.8 13.3 
10.8 13.2 12.4 13.0 
6.8 8.9 9.7 9.3 
2.7 2.4 4.3 5.3 
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1 (iii) Prevalence of Malignant Disease in Adolescent 
The malignant lymphomas, germ cell tumors and brain tumors account for 
almost 5()OA, of the total, a distribution different from that in children and 
adults. Acute myeloid leukemia, diffuse large-celllymphoma are common 
and amongst soft tissue sarcomas, non-rhabdomyosarcomatous variants 
predominate. 
Gender differences in incidence are obvious with the M:F ratio ranging from 
a value of more than 2 for ALL to a striking reversal for thyroid carcinoma 
which occurs in young women. Osteogenic sarcoma has a ratio of 1,6. 
Ewing sarcoma of 1,8 and soft tissue sarcomas 1,2. 
In South Africa the National Cancer Registry is pathology based (Mqoqi N, 
1996-1997). The age specific incidence rates per 100,000 indicate the 
following: 














In the 15-19 year age group: 
(i) Bone 
(ii) Leukemia 
(iii) Hodgkin's Disease 
(iv) Non-Hodgkin's & Brain 
In the 20-24 year age group: 
(i) Basal Cet! Carcinoma 
(ii) Cervix 
(iii) Breast 





















This report is at variance with what is reported in world literature but the 
accuracy in the reporting is questionable as the registry relies on the 
different laboratories to report all cases. These results, therefore, are the 
outcome of incomplete ascertainment and emphasize the need for a 
complete registry. 
1 (iv) Venous Access Devices IVADl 
The Oncologist faced with the clinical problem of drawing blood and 
administering chemotherapy or the palliative care physician who may need 
to draw blood, administer antibiotics, deliver fluid and nutritional support and 
at times administer analgesics has three choices to choose from when the 
patient will need treatment over a protraded time: a) Rely on peripheral 
veni-pundure in the face of ever deteriorating peripheral veins. 
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b) Insert a form of Hickman-Broviac catheter which emerges through the 
skin and can be left in-situ for the medium term. c) Insert a totally 
implantable venous access device (V AD) or port to which is attached a 
central venous catheter. 
The VAD can minimize the discomfort of: i) Repeated veni-puncture, ii) 
Venous thrombosis and thrombo-phlebitis caused by repeated veni-
puncture, iii) Maintain patient mobility and allow him the use of both hands 
during treatment, iv) Minimize hospital stay. VADs therefore can improve 
the quality of life in patients with cancer that need repeated intravenous 
procedures during their illness. 
(a) Tyoes of Devices 
A Catheters 
In all indwelling catheters used for prolonged central venous access, the 
proximal capped portion exits from the subcutaneous tunnel on the chest or 
abdominal wall while the distal tip is indwelling in a central vein (Goodman 
MS, 1985& BroviacJW, 1973). 
i) Silicone elastomer catheters with a simple opening at the distal tip 
include a variety of peripherally inserted central lines viz the 
Hickman-Broviac(Hickman RO,1979, & Anderson KM, 1992) 
catheters and Groshong tip catheter. These catheters can be 
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tunneled under the skin and have a Daaon cuff which is inserted in 
the subcutaneous tissue just above the exit site. 
ii) Peripherally inserted central catheters (PICC) (James L, 1993 & 
Banton J, 1999). Advantages include ease of insertion and low risk 
of serious complications. If maintained properly these lines can last 
as long as one year and can be used for chemotherapy (Niederhuber 
JE,1982) or total parenteral nutrition (Alhimyary A, 1996). 
B. Implanted Devices 
Since their introduction, implantable ports have become popular with 
patients and clinicians alike (Niederhuber JE, 1982). These devices are 
constructed from ,a variety of materials including titanium and plastic and 
can be made compatible with magnetic resonance imaging (MRI) and 
computed tomography (Ross MN, 1988). The general design includes a 
compressed silicone diaphragm which can withstand multiple punctures with 
a Huber needle. These ports are inserted in the operating room. 
The port housing is placed in a subcutaneous pocket on the chest wall. The 
housing is anchored to the underlying fascia by several interrupted sutures. 
Improvements in the port design have allowed for the construction of a very 
low profile, small device that can be implanted. Comparisons between 
these devices, standard Port-o-Caths and external catheters have shown 
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that both the Port-o-Cath and PAS-port have a reduced incidence of 
infectious complications when compared to extemal catheters (Sharpe 
PC,1994). Whilst one retrospective study noted no difference in infection 
rates between Hickman-Broviac catheters and ports, three prospective non-
randomized studies indicated a significantly lower complication rate for the 
ports than catheters especially in younger children (Mirro J, 1990 & Wurzel 
Cl, 1988 & lucas AB, 1992). 
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(b) Complications 
The complications associated with VAD can be divided into: 
1. Those occurring during the placement of the device, such as Arterial 
Pundure, Cardiac Anhythmia, Cardiopulmonary arrest, 
Pneumothorax and incorred placement of catheter. In a published 
series undertaken (Decker MD, 1988), the incidence rate of the 
above complications were 5.2%,1.6%,0.1 %,0.5% respectively. 
2. Damage to the external segment of the catheter can occur due to 
repeated damping of the external comedion. Cuts made by scissors 
mistaken for damps have been performed. 
3. The VAD may "fliP- within the pocket because of excessive arm 
movement or because of manipulation by the patient. 
4. Phlebitis and Infiltration. These are uncommon complications 
associated with proper1y positioned centrally placed VADs, but are 
commonly seen with peripherally positioned catheters. 
5. Infedions. The incidence of infedious complications varies 
depending on the type of device use. Overall the incidence of 
catheter associated infedions is 1-2 per 1000 days of patient use 
(Decker MD, 1988). Exit site and tunnel infedions are caused by 
baderia of which most will respond to antibiotics alone and for 
catheter removal. Most are caused by S.epidermis and S aureus. 
Other organisms indude Streptococcus sp and Gram negative rods 
namely Pseudomonas and xanthomonas. Fungal infections mainly 
Candida spp and Aspergillus spp are also well known pathogens 
(Decker MD, 1988). 
6. Hemorrhage. In patients with known thrombocytopenia and also in 
patients with Disseminated Intravascular Coagulopathy post 
operative bleeding does occur. 
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7. Thrombosis. Clot formation can occur in the catheter itself or in one 
of the major vessels of the upper extremity. The thrombosis usually 
results from failure to follow standard flush procedures. Thromboses 
were seen in 16% of implanted ports (Press OW, 1984). 
8. Vesicant Drug Extravasation. It is unusual for a spontaneous leak to 
form in a large bore catheter, but an attempt to irrigate an occluded 
catheter with a small syringe can cause a rupture, through which drug 
can extravasate (Goodman MS,1985). Occlusion of the catheter tip 
by a fibrin sheath may force the drug back up the sheath and through 
the exit site of the catheter (Bottino J, 1979). Leaks may occur if the 
catheter is disconnected from the reservoir or if the catheter is 
punctured by mistake by the Huber Needle. In addition outpatients 
using a port for continuous infusion chemotherapy can suffer drug 
extravasation if the Huber needle dislodges from the septum (Lucas 
AB,1992). 
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1 (v) lbe Impact of Cancer Diagnosis on Quality of Life (QQL) 
What is quality of life? Conceptually, QOL is a vague term and most people 
would agree that QOL is not a unitary concept, but a complex amalgam of 
satisfactory functioning in essentially four core or primary domains, viz. 
psychological, b) social, c) occupational, d) physical. 
Most items contributing to well-being and life's quality can be listed within 
one or other of these domains and there is obviously considerable overlap. 
One feature about good health i.e. relating to the physical domain of QOL is 
that it is noticed more by its absence than by its presence. In adolescents 
with cancer, having to be isolated from peers and society by having a 
disease that makes them different and having to be treated separately is 
often devastating. In addition, many of the adverse effects of therapy can 
be overwhelming to an adolescent's self-image, which is often tenuous 
under the best of circumstances (Woo SY, 1983). Weight gain, alopecia, 
acne, stunted growth, and mutilating surgery to the face and extremities are 
examples of adverse consequences that can be devastating to an 
adolescent's self-image. Repeated venepuncture with needles in order to 
draw blood and/or administer therapy is a constant source of anxiety and 
pain for adolescent patients. Other challenges include the time away from 
friends, school, work, and community that therapy requires and the financial 
hardships that occur at an age when economic independence from family is 
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an objective. Although cancer and other chronic diseases in younger and 
older patients have been shown to increase cohesion among families of 
affected persons, survivors of cancer during adolescence actually report 
lower levels of family cohesion than healthy adolescents and their families 
(Festa RS, 1992). The knowledge of having a life-threatening disease can 
seriously impair the quality of life of patients. This occurs in individuals who 
have a good understanding of the implications of the disease and treatment, 
but is notably worse in those with a poor comprehension of cancer and its 
treatment. 
1 (vi) Intravenous Therapies 
The complex management of the patient with cancer frequently relies on the 
ability to deliver a variety of intravenous agents over a prolonged period. 
Chemotherapy, blood and/or blood products, total parenteral nutrition and 
analgesics may all be required alone or in combination. All require secure 
access to the circulation as does venous sampling which in such patients is 
a frequent procedure. Extravasation of chemotherapy agents into the 
tissues can result in massive tissue destruction even if recognized and 
treated early. Secondly the veins of the upper limbs are quickly rendered 
inaccessible by repeated use and the fragility of some veins is the cause of 
serious local necrosis and tissue destruction. 
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AIMS AND OBJECTIVES OF THIS DISSERTATION 
1. 
(i) To retrospectively review the records of patients 21 years and 
younger at the time of initial treatment that had been seen and treated at the 
Mary Potter Oncology Center who had a venous access device inserted to 
aid in their therapy. 
(ii) To note the specific complications occurring due to the VAD. 
(iii) To evaluate the data of those patients with a VAD who completed the 
EORTC QlQ -C30 (a quality of life questionaire) during the course of 
their cancer. 
2. To determine the average financial cost of VAD in patients with 
cancer with specific reference to: 1) hospital costs to insert the port. 2) 
additional costs associated with complications. 3) day to day costs. 
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MATERIALS AND METHODS 
All patients were seen and treated at the Mary Potter Oncology Centre in 
Pretoria by the four resident medical oncologists. The records of those 
patients who were 21 years and younger at the time of the first consultation, 
between May 1999 and November 2003, were reviewed. All patients had a 
VAD inserted prior to chemotherapy administration. 
A VAO 
Intravenous access was obtained using a VAO in 51 patients. Three 
patients had 2 V ADs inserted. Various totally implantable titanium venous 
access port systems were used with a silicone rubber catheter (00 2.8 mm 
and 10 1.0 mm). The implantation procedure required the use of a no. 7 
French peel-away introducer; a modified Seldinger technique was used for 
cannulation of the subclavian vein. VAOs were implanted under general 
anaesthesia by one of four surgeons who had agreed to follow a 
standardized implantation procedure (Strum S, McDermed J, 1986). 
Materials used for VAD 
Standard sets of supplies for VAO accessing included two sterile towels, 
one alcohol swab, three povidone-iodine swabs, one pair of sterile gloves, 
one 20 ml syringe, one Huber needle, two 21-gauge needles, 100 U/ml 
heparin solution for anticoagulating the VAD reservoir, and one vial of sterile 
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0.9% saline for flushing the VAD reservoir and catheter. VAD phlebotomy 
required one additional 1 0 ml syringe for discard and one additional 20 ml 
syringe for the blood sample. Treatments that were administered through 
these devices included: 
1. All chemotherapy - the different chemo-therapeutic regimes given 
were according to specific internationally acceptable protocols and 
included 2, 3 or more drugs. The main drugs used for these patients 
were: 
(i) Doxorubicin and other anthracycUne derivatives 
(ii) Cisplatinum and Carboplatinum 
(iii) Cyclophosphamide and IphosphamidelMesnum-alkyiating agents 
(iv) Vincristine, Vinblastine - Vinca alkaloids 
(v) Etoposide 
(vi) Actinomycin-D. 
2. Additional fluid therapy. Certain chemo-therapeutic drugs require the 
additional administration of intravenous fluid in order to minimize 
organ damage e.g. pre- and post-hydration fluid given concurrently 
with Cisplatinum. These fluids are given over a few hours and are a 
vital part of therapy. 
3. Supportive drugs such as (i) anti-nauseants induding 5HT 3 blockers 
such as Ondansetron, major tranquilizers such as Chlorpromazine. 
(ii) Corticosteroids such as methyl-prednisolone and Dexamethazone 
are given intravenously in order to prevent nausea and vomiting. 
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These are given prior to initiation of the chemotherapy and at regular 
intervals during the specific treatments. As most chemotherapy 
drugs, and especially these used to treat the diseases seen in 
younger patients, are highly emetogenic venous access is paramount 
for administration of anti-nauseants. 
4. Blood and platelet transfusions. These are usually needed at some 
stage during the course of therapy as patients may become anaemic 
or thrombocytopenic. This may due to the effects of the cancer and 
of the treatment thereof. 
5. Antibiotics. These may be required if the patient develops infection 
as a result of neutropenia caused by the chemotherapy. If the 
infection is severe, hospitalization in isolation wards is necessary and 
prolonged intravenous antibiotics may be required to combat 
infection. 
6. Total parenteral nutrition (TPN). Mucositis also may result from the 
chemotherapy. This can prevent adequate oral fluid and food intake. 
In order to treat this complication, TPN is given usually in the hospital 
setting and it too may require prolonged administration. 
7. Intravenous hydration in the terminal phase of the patient's life. Many 
patients' families insist that patients receive hydration during the final 
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phase of their lives. Having a VAD facilitates the administration of 
fluid and has the advantage that this can be done at home. Other 
drugs used during this phase can also be administered intravenously 
such as anti-nauseants, analgesics, anti-convulsants, anxiolytics and 
major tranquilizers. 
B. The EORTC QlQ-C30 (See Appendix 1) is a 30 item instrument 
composed of multi-item scales and single items that reflect the multi-
dimensionality of the quality-of-life construd (QOl) (Aaronson NK, 
Ahmedzar S, 1993). It incorporates five fundional scales (physical, role, 
cognitive, emotional and social) three symptom scales (fatigue, pain, 
nausea and vomiting) and a global health and quality-of-life scale. The 
remaining single items assess additional symptoms commonly reported by 
cancer patients (dyspnoea, appetite loss, sleep distU'bance, constipation 
and diarrhoea) as well as the perceived financial impad of the disease and 
treatment The questions are formatted with either yes or no answers, or by 
using four answer categories that range from 1, not at all, to 4, very much. 
The two questions on general health and global QOl are answered on a 
numbered visual analog scale from 1 to 7. The questionaire has been 
tested in over 12 countries and has demonstrated high validity in different 
cancer patient populations (Ringdal GI. 1993). 
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18 Patients completed a Quality of Life questionaire at each visit during the 
time period that they received their chemotherapy. This was usually every 
3-4 weeks. A validated 'computer touch screen' version installed at the 
Mary Potter Oncology Centre was used by the patients. All 18 patients 
completed the questionaire without any assistance. The time taken to 
complete such a questionaire is between 3 and 5 minutes. All data is 
electronically stored and can be displayed and compared on the screen 
according to dates of visits. 
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DATA ANALYSIS 
Statistical analysis was conducted using S~ system (Version 9.1): 
• To determine mean and median survival time estimates, the Kaplan-
Meier life table estimates were used (Kaplan-Meier, 1958). 
• To explore the differences in quality of life determinants over 3 points in 
time, the repeated measures ANOVA (Analysis of Variance) was used 
(Stuart A, 1991). 
The 3 points in time relating to the port insertion were: 
(i) Before the insertion of the port (time 1 ). 
(ii) From time of port insertion up to and including 53 days thereafter 
(time 2). 
(iii) Anytime after 54 days (time 3). 
The scales of the EORTC..QLQ-C30 served as dependent groups and 
points of time served as independent variables. 
I SAS is a registered ttademark of the SAS Institute 
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In order to see if an observed difference or relationship reflects the real 
pattern rather than just a chance anomaly a statistical hypothesis test is 
performed. Two hypotheses are formulated, the first called the null 
hypothesiS which states that there is no real relationship or difference. The 
second called the alternate hypothesis, reflects the possible ways in which 
the null hypothesiS could be false. To assess the evidence for the 
alternatives, a test statistic, which reflects the degree to which the sample 
results tend towards the alternative hypothesis, is calculated. This 
determines a probability, called the p-value, which is the probability that the 
observed findings would occur if the nul hypothesis were true. If this is 
unlikely (usually set at less than 1 in 20 possibility that the observed finding 




(i) There were 51 patients who had 54 ports inserted. 37 Patients were 
male. 
(ii) Their mean and median age was 17 years (9-23 years). 
34 Patients were still alive at time of analysis. 
(iii) The spread of diseases of the group were as follows: 
Disease Patients 
1. SarcomalPNET patients 21 
2. Lymphoma 13 
3. Leukemia 8 
4. Medulloblastoma 2 
5. Aplastic Anaemia 2 
6. Testis Carcinoma 1 
7. Dysgerminoma 1 
8. Melanoma 1 
9. Nasopharynx 1 
10. Kidney Cancer 1 
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(iv) Response to therapY 
• 24 Patients attained a complete response to therapy. This means that 
all demonstrable disease had completely resolved when measured on 2 
subsequent visits at least one month apart with no evidence of new 
lesions. 
• 15 Patients achieved a partial response. This is defined as all 
measurable and evaluable disease dea'easing by at least 50% on two 
separate occasions at least one month apart with no evidence of new 
lesions. 
• 2 Patients had an improvement in disease status implying that the 
response was less than 50% and no new lesions present. 
• 5 Patients had no change in their disease status. 
• 5 Patients had progressive disease as their main response. This ocrurs 
if there is at least a 30% increase in size of measurable disease or the 
appearance of any new tumor lesions. 
(v) Survival 
The median sLlVival time of all these patients was 86 months and the mean 
survival time was 64 months. After truncating the graph at 40 months, 
which is reasonable given that there were only 6 individuals still alive, no 
median survival could be estimated. (Graph I). 
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• No significant differences in survival could be shown for any particular 
subgroup of "Response to therapy". 
-24. 
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IV) VAO Complications 
Of the 54 VADs Inserted the following complications were encountered 
t 7 Fractures AUlhe fractures were althe connecllon of the VAD to 
the reservoir In aU cases the VADs were removed successfuUy The 
broken VAD hnes were also removed successfuUy. either by ' snanng" 
them With a gUide-WIre passed t\Tough the femoral vem Into Ihe 
Inferior vena cava and nght alI1\i1Tl (6) 01' through sternotomy and 
cardiotomy (1) 
2 SepsIs. Both cases had Gram posltwe COCCI cuttured In their blood 
These lWfe Coagulase negative StapnylococCl 
3 1 Too shaUow with erosion tlYough the skin 01 the mest wall 
4 1 Tilt With resultant Inability to Insert the needle 
5 t Hemothorax at lime of Insertion 
6 1 Jugular Veln tlTOmboSIS OCClJmng long after Insertion 
Total 13 
All these necessitated removal of the VAD 
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(VI) At The Time Of Analysis 
• 22 palientS had their VAD In Situ for a mean of 15 7 monlhs (1,2 - 38) 
• 14 Patients had died Md their VAD had no! been removed The mean 
duration of VAD-m .... srtu was 7,4 months (2,1 - 23) 
• 18 VADs were Inserted and then removed after a mean durallon of 7,5 
months (0. 1 - 13,9) 5 VADs were removed as the patients had 
completed their therapy and 13 VADs were removed due to a 
compllcahan 
• For al i ltle VAOs, lhe median ' port SUtVlVal' was 10.57 months (See 
Graph II ) 
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Quality of Life Assessment 
Table II shows the results of multlvanate tesls performed on Itle EORTC· 
OLO-C30 sub-scales All flXlctlonal scales, symptom scales and global 
health and quality of life scale were chosen as well as the addi tional 
symptom scale 
A comparison of the pOints in time for each sub-scale gave the following 
results 
1 Improvement of symptoms was signi ficant as time progressed for 
fatigue (p = 0.005), nausea (p = 0,02). appetite (p = 0,04). Insomnia 
(p = O. 048) with the least symptoms experienced In TIme 3 I.e. the 
furthest time from baseline 
2. Although nol significant, financial (p " 0.08), constipation (p = 0,188). 
also followed a Similar trend with less symptoms being present at the 
furthesilime from baseline 
3 For lhe functional sub-scales. a deterioration In functioning was 
present at the time of VAD placement and up to 53 days thereafter 
for the following Cognitive (p=0.045), role (p=0,069), SOCial (p=O 05) 
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4 For both the Global healthy and quality 01 hfe scale (p=O,29) and 
physical scale (p:O,65), the rughest (besl) saxe was obtaIned the 
furthest l ime sInce VAD InsertIon (TIme 3) 
5 At tIme of the VAD Insertton the follOWIng sub-scales showed the 
hIghest level of problems and lowest level of funcbof'lIng i) CognitIve, 
(II) emotIonal, (I") role (IV) sooal (v) appellte, (VI) constIpatIon, 
(VII) diarrhoea, (viii) dyspnoea, (u() finanaal , (x) Insomma (XI) 
nausea and emollonal scale 
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FINANCIAL COST 
Table 3 The costs in rands associated with VAD insertion, removal and 
monthly "flushing". The insertion of a VAD requires the follOWing procedures 











including ward, theatre 

















The cost of "flushing a porr performed every time blood is withdrawn 
includes items: 
1. Whin needle R28.oo 
2. Dressing pack 15.39 
3. Heparin 23.52 
4. Gloves 7.27 
5. Primapore 6.36 
6. Syringe (5 ml) 4.62 
Total: R85.16 
Venous accessing costs were estimated in November 2003. 
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DISCUSSION 
This study evaluated information on the patients seen and treated at a 
single institution who were 21 years or younger and who had the diagnosis 
of cancer. All of these patients had VADs inserted to facilitate ease of 
administration of therapy as it was assumed that by inserting a VAD, the 
patient's quality of life would be improved. 
The incidence of the diseases of the patients who were evaluated, was 
biased in that most adolescent and paediatric patients with haematological 
diseases and neoplasms are seen at other specialized academic units in 
govemment hospitals. The Mary Potter Oncology Center has a reputation 
for treating adolescents with sarcomas and is therefore a major centre of 
referral in Gauteng. The incidence rates of malignancy in these age groups, 
as reported for South Africa, is at variance with those reported for the USA 
and UK This may in part be explained by under-reporting of tumors that 
occurs in South Africa. 
Clinical trials to evaluate safety and efficacy of VADs have been single arm 
Phase II studies: (i) Gyves J, et ai, 1982; 
(ii) Becton DL, et ai, 1988 
(iii) Strum S, et ai, 1986 
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Or: Non-randomized studies: (i) Ingram J, et ai, 1991 
(ii) Stanislav G, et ai, 1987 
Or: Randomized studies: (i) Carde P, at ai, 1989 
(ii) Kappers-Klunne MC, et ai, 1989 
A number of authors have desaibed the dinical complications associated 
with VADs, the most important being infection, although mechanical 
problems such as thrombosis are also frequent. In a retrospective review of 
645 port systems a complication rate of (8,4%) was reported, with the 
common complications being infection (58%) and thrombosis (22%) and 
cases of port fracture (5,5%) (Chevral JP, 1996). In another series (Ingram 
J, 1991), of 144 subcutaneous ports, 46 (32%) were removed. The main 
complications were infection (4%), occlusion (1,4%), inadvertent needle 
dislodgement (1,4%), catheter rupture (1,4%), and mechanical occlusion 
(0,7%). In a further series (O'Neill, 1999), 110 Hickman catheters were 
inserted in 94 patients with solid tumors undergoing treatment with 
chemotherapy. Ear1y complications included pneumothorax (4%), arterial 
puncture (1%), failure of placement (1%). Late complications induded 
sepsis (24,5%), thrombosis (9%), line displacement (10%), and catheter 
blockage (1 %). In the first randomized controlled trial which compared the 
use of totally implantable venous access devices before chemotherapy with 
standard peripheral venous access (Bow EJ, 1999), only 2 of 119 
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assessable patients crossed from VAD to peripheral line access because of 
VAD occlusion and catheter fracture. 
In our series of 54 VADs, the major complications were a 'port fracture' in 7 
V ADs (13%), and sepsis with gram positive cocci (coagulase negative 
Staphylococci) in only 2 VADs (3,7%). The majority of the fractures 
occurred after long term use of the V AD and usually once the treatment had 
finished. No consistent problem with technique insertion could be 
determined. As the VADs were inserted by a number of different surgeons, 
no operator problem could be identified either. The broken catheter tips 
have been sent back to the manufacturers for assessment of the material 
used. 
The quality of life parameters used represent a wide spectrum of the 
patient's life. The QLQ-e 30 was initially tested for validity based on 
comparisons between patient subgroup who were known to differ in dinical 
status. The QLQ-e 30 was less successful in disaiminating between 
patients with different stages of disease, but was dearly able to distinguish 
between patients differing in terms of performance status, weight loss and 
treatment toxicity. An essential property of a quality of life instrument 
intended for use in the dinic is that it be responsive to changes in patients' 
health status over time. The QLQ-e 30 has shown statistically significant 
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changes in functional and symptom levels in the expected direction for 
patients whose performance status has either improved or deteriorated and 
no shifts in QLQ-C 30 scores were observed for those patients whose 
performance status remain unchanged over time (Aaronson NK, 1993). The 
present study demonstrates a trend to decrease in fundional and well as 
symptom scores in the period of VAD insertion and up to 53 days post 
insertion. The most significant deterioration of score in the time period 
being cognitive, role and social fundioning. There is evidence that 
chemotherapy per se can affect brain biochemistry directly, which results in 
mood disturbance and other cognitive impairment (Silberfarb 1980). It is 
possible then that patients who received chemotherapy within the same time 
frame as having the VAD inserted did have a decrease in their cognitive and 
other fundioning, due to in part, by the chemotherapy. The scale assessing 
role fundioning is amongst the briefest scales within the QLQ-C 30 and has 
the most restrided range of responses. Also the content area covered is 
limited to work and household adivities and no leisure time adivities are 
included. For younger patients the applicability of this limited range may not 
be a true reflection of what their role functioning really is, as the assessment 
may lack the necessary questions to truly assess an adolescent's role 
functioning. In the QOL study in-patients who had either VAD or peripheral 
lines (Bow EJ, 1999), QOL studies were performed to examine whether 
VAD use could influence fundional quality of life. The instrument used was 
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the FLI-C (Clinch JJ, 1996). ,Although the VAD use reduced the venous 
access trauma and discomfort, no measurable improvement in quality of life 
attributable to the VAD could be demonstrated. It is important to remember 
that patients with cancer have special medical and psychiatric concerns, 
including fear of termination of treatment, pre-occupation with disease 
recurrence and minor physical problems and a sense of greater wlnerability 
to illness (Damocles syndrome). Also a pervasive awareness of mortality 
and difficulty with re-entry into normal life (the Lazarus syndrome). All of 
these fears have a profound influence on quality of life. Adolescents who 
have been treated for cancer not only have substantial physical, cognitive, 
emotional and interpersonal tasks faced by all adolescents but have the 
added burden of a life threatening disease. Persistent body image 
concerns, somatic-preoccupation, disruptions in sexual relationships and 
deficits in social competence are not uncommon (Mulhern R, Wasserman A, 
1989). All of these fadors have a profound influence on the adolescent and 
hisJher fundioning in all spheres and therefore would all affed the quality of 
life evaluation. 
The financial costs involved have been studied and estimated in other 
studies (Bow EJ, 1999). Although it is impossible to assign a monetary 
value to human suffering related to vascular access problems, the reported 
average cost of accessing and maintaining a VAD for approximately 7 
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months in patients with cancer is $2000. This represents over a billion 
dollars spent per year on VAD, in the USA This is a conservative estimate 
as the projection does not take into account the costs of other access 
devices that have a higher complication rate and patients who require longer 
or more intensive chemotherapy (Freytes CO, 1999). This present study 
also under-estimated the costs in that the nursing time needed for flushing 
was not accounted for. Neither the extra costs of removing a fractured line 
of the VAD nor the additional antibiotics, fibrinolytics and anti-coagulants 
needed to treat the complications have been induded in the calculation. 
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CONCLUSION 
The evaluated quality of life scores in the patients who had VADs inserted to 
facilitate administration of treatment show a decrease in most parameters at 
the time of the VAD insertion and up to 53 days thereafter. This is then 
followed by an increase in QOL parameters to over and above the initial 
levels. Results from studies of adolescents with cancer show that there are 
long-term survivors. Complication rates due to VAD use are not particularly 
high, and the initial deterioration in QOL scores are temporary. The prime 
advantages of having a VAD are the convenience of ease of administration 
of treatment, convenience and safety of the venous access. 
Future studies should evaluate the teenagers QOL with more specific 
questionaires relating to an adolescents QOL. Only then can an honest 
argument be presented to a patient to allow for an informed decision to be 
made regarding insertion of a VAD. 
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